Hexacationic Ruthenium Metallaprism  Metallaprism mainly affects lipid metabolism in A2780 (human ovarian cancer) and HEK-293 (human embryonic kidney) cells, and increases GSH levels in all cell lines. In A2780cisR (cisplatin resistant A2780) cells, lipid biogenesis and glycosylation are affected by treatment with metallaprism.  HR-MAS:a)1D-1H NOESY-1H CPMGb)2D-1H,1H-TOCSY-1H J-resolved  [138]